RLAY · Relay Therapeutics, Inc.

Track RLAY — free

$19.77 +0.07 (+0.36%)

Market Cap

$4.32B

219.14M

Up next

Next earnings call

May 17, 2027 Est · unconfirmed · in 38 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 6, 2026

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +61%

above

Price vs 50-day avg +6%

above

RSI (14) 52

neutral

MACD trend Negative

52-week position 94%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +3%

trailing

6-month return +92%

trailing

YTD return +133%

this year

Relative strength +81%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $19 › 200d $12 — 50d above 200d

Institutional flow Accumulating

+6% holders QoQ · +52 funds added

Insider flow Distributing

Net -$82.7K over 90 days · 100% sells

Short interest Falling

18.37% of float · ▼ -5.4% MoM · 17.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

259 holders — near 3-yr high, broad support

Squeeze score 81

high risk · 0–100

Fundamentals

Strong

Revenue growth +53%

Y/Y

EPS growth +32%

Y/Y

Free cash flow $-235.9M

Balance sheet $84.0M

net cash

Quant / Vol

risk profile

Very High

Volatility 70%

annualized · 1-yr

Max drawdown −28%

past year

ATR 5.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+61% Bullish

Price vs 50-day avg

+6% Bullish

RSI (14)

52 Neutral

MACD trend

Negative Bearish

52-week position

94% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $19 › 200d $12 — 50d above 200d

Institutional flow Accumulating

+6% holders QoQ · +52 funds added

Insider flow Distributing

Net -$82.7K over 90 days · 100% sells

Short interest Falling

18.37% of float · ▼ -5.4% MoM · 17.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

259 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $3 Now $20 · 94% Range high $21

vs 200-day avg +61% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
gross proceeds	$316M	May 2026	—
patients with HR+/HER2- breast cancer with a PI3Kα mutation	140,000	per year in the United States	—
patients with vascular anomalies driven by a PI3Kα mutation	170,000	per year in the United States	—
volumetric response	60%	the earliest time point (12 weeks)	—
11.1-month median PFS	11.1	first quarter 2026	—
median PFS in kinase domain mutations	11.2	first quarter 2026	—
Objective response rate (ORR) for zovegalisib triplet	44%	first quarter 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
RLAY Relay Therapeutics, Inc. this stock	$4.32B	+132.9%	+53.4%	—	18.4%
ONC BeOne Medicines Ltd.	$557.05B	+21.5%	+22179.2%	856.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+19.2%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.39B	+7.1%	+20.8%	20.8	3.3%
MRNA Moderna, Inc.	$69.62B	+352.1%	+4.3%	—	12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

259

% held: 113.9%
Net QoQ: +64.1M sh
Top holder: SB INVESTMENT ADVISERS (U…

Held Float

View

Held by Funds

Fund positions

236

View

Short & Settlement

Short Interest Falling

Shares short

40.3M

Days to cover: 17.4d
Change: -2.3M sh

View

Short Volume

Short vol %

81%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $1.6K
As of: Jul 23, 2026

View

Off-Exchange

Off-exchange %

42.7%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$82.7K

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Jul 12, 2023

View

Financials

Revenue (FY)

$15.4M

Net income (FY): $-276.5M
EPS diluted: $-1.61

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 19

View

Proposed Sales

Value

$826.5K

Shares: 42.2K
Filed: Aug 4, 2026

View

Exempt Offerings

Offering

$30.0M

Filed: Jan 10, 2024

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
RLAY	-1.2%	+3.2%	+92.0%	+4.6%	+132.9%
SPY	-2.0%	+3.3%	+11.2%	+2.1%	+11.8%
vs SPY	+0.8%	-0.1%	+80.8%	+2.5%	+121.0%

Key facts CIK 1812364 CUSIP 75943R102 13F (30d) 249 filings 243 filers Visit website Investor relations

RLAY · Relay Therapeutics, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance